Plus Therapeutics Stock Analysis

The latest indifference towards the small price fluctuations of Plus Therapeutics may encourage sophisticated investors to take a closer look at the company as it is trading at a share price of 0.0 on very low momentum in trading volume. The company directors and management did not add any value to Plus Therapeutics investors in June. However, most investors can still diversify their portfolios with Plus Therapeutics to hedge their inherited risk against high-volatility market scenarios. The stock standard deviation of daily returns for 90 days investing horizon is currently very low. The very small Stock volatility is a good signal to sophisticated investors with longer-term investment horizons.
Check out Your Equity Center.

Search Stock Analysis 

The Plus Therapeutics stock analysis report makes it easy to digest most publicly released information about Plus Therapeutics and get updates on important government artifacts, including earning estimates, SEC corporate filings, and announcements. Plus Therapeutics Stock analysis module also helps to analyze the Plus Therapeutics price relationship with some important fundamental indicators such as market cap and management efficiency.

Plus Therapeutics Stock Analysis Notes

The company recorded a loss per share of 30.62. Plus Therapeutics had not issued any dividends in recent years. The entity had a split on the 6th of August 2019. Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer and other diseases. Plus Therapeutics, Inc. was founded in 1996 and is headquartered in Austin, Texas. Plus Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 12 people. To find out more about Plus Therapeutics contact Marc Hedrick at 737 255 7194 or learn more at

Plus Therapeutics Investment Alerts

Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Plus Therapeutics' investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Plus Therapeutics or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
Plus Therapeutics is not yet fully synchronised with the market data
Plus Therapeutics has some characteristics of a very speculative penny stock
The company reported the previous year's revenue of 185 K. Net Loss for the year was (9.87 M) with loss before overhead, payroll, taxes, and interest of (2.4 M).
Plus Therapeutics currently holds about 14.45 M in cash with (9.94 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.68.

Plus Therapeutics Market Capitalization

The company currently falls under 'Micro-Cap' category with current market capitalization of 45.17 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Plus Therapeutics's market, we take the total number of its shares issued and multiply it by Plus Therapeutics's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities.

Management Efficiency

The entity has return on total asset (ROA) of (28.12) % which means that it has lost $28.12 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (205.75) %, meaning that it created substantial loss on money invested by shareholders. Plus Therapeutics management efficiency ratios could be used to measure how well plus therapeutics manages its routine affairs as well as how well it operates its assets and liabilities.

Plus Therapeutics Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Plus Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Plus Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Plus Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.

Plus Therapeutics Technical and Predictive Indicators

Be your own money manager

As an investor, your ultimate goal is to build wealth. Optimizing your investment portfolio is an essential element in this goal. Using our stock analysis tools, you can find out how much better you can do when adding Plus Therapeutics to your portfolios without increasing risk or reducing expected return.

Did you try this?

Run Portfolio Backtesting Now


Portfolio Backtesting

Avoid under-diversification and over-optimization by backtesting your portfolios
All  Next Launch Module
Check out Your Equity Center. Note that the Plus Therapeutics information on this page should be used as a complementary analysis to other Plus Therapeutics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try ETF Directory module to find actively traded Exchange Traded Funds (ETF) from around the world.

Other Tools for Plus Therapeutics Stock

When running Plus Therapeutics price analysis, check to measure Plus Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Plus Therapeutics is operating at the current time. Most of Plus Therapeutics' value examination focuses on studying past and present price action to predict the probability of Plus Therapeutics' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Plus Therapeutics' price. Additionally, you may evaluate how the addition of Plus Therapeutics to your portfolios can decrease your overall portfolio volatility.
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
Headlines Timeline
Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
Probability Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years
Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account
Global Correlations
Find global opportunities by holding instruments from different markets
Content Syndication
Quickly integrate customizable finance content to your own investment portal
Performance Analysis
Check effects of mean-variance optimization against your current asset allocation